Eli Lilly and Company $LLY Shares Sold by 111 Capital

111 Capital reduced its position in Eli Lilly and Company (NYSE:LLY) by 56.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 654 shares of the company’s stock after selling 864 shares during the quarter. 111 Capital’s holdings in Eli Lilly and Company were worth $499,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Exencial Wealth Advisors LLC raised its stake in Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after purchasing an additional 11,396 shares during the last quarter. Rede Wealth LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $487,000. Central Pacific Bank Trust Division grew its holdings in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after buying an additional 1,843 shares in the last quarter. Cidel Asset Management Inc. lifted its stake in shares of Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after buying an additional 5,591 shares during the period. Finally, Oak Family Advisors LLC purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $1,979,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,007.37 on Wednesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The firm’s 50-day simple moving average is $1,050.71 and its 200-day simple moving average is $936.44. The firm has a market cap of $950.31 billion, a PE ratio of 43.89, a price-to-earnings-growth ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Bank of America reduced their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research note on Monday, December 15th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft upped their price target on Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly says it is preparing to launch its oral obesity drug orforglipron in the U.S. as soon as Q2 pending FDA approval — a major revenue catalyst if approved and on schedule. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: Lilly won CHMP backing to expand Olumiant (baricitinib) use in adolescents with severe alopecia areata, which could broaden EU label and incremental sales. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Lilly advanced remternetug Alzheimer’s testing in China, extending its CNS pipeline geography and potential long‑term growth optionality outside the U.S. Lilly Advances Remternetug Testing in China
• Positive Sentiment: Lilly advanced a Phase 1 oral diabetes candidate in China, reinforcing its diabetes/GLP pipeline breadth beyond injectable and obesity programs. Eli Lilly Advances New Oral Diabetes Drug In China
• Neutral Sentiment: Analyst coverage remains constructive overall (average “Moderate Buy”) and industry outlooks highlight Lilly as a core large‑cap pharma to watch, supporting longer‑term investor interest. Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Investor attention pieces and conference transcripts (TD Cowen) are circulating — helpful for transparency but not immediate stock drivers. TD Cowen Presentation Transcript
• Negative Sentiment: Competitive pressure: Novo Nordisk’s $506M expansion in Ireland signals stronger manufacturing scale for oral GLP medicines, a direct competitor to Lilly’s obesity/GLP lineup and a potential market‑share headwind. Why Novo Nordisk’s Ireland expansion is key
• Negative Sentiment: Some editorial/analyst pieces argue investors should consider alternatives or note that Lilly’s valuation and recent momentum have cooled after a multi‑year run, increasing sensitivity to any negative headlines. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.